|
WASHINGTON (AP) - Federal advisers are considering whether a proposed weight-loss drug raises the risk of depression, a finding that could lead to stern warnings on the medication if it is approved.
Sanofi-Aventis AS has told the Food and Drug Administration it wants to sell the drug rimonabant under the brand name Zimulti. Concerns about its psychiatric effects have delayed a final FDA decision on the medication. The agency previously told the French company it would not approve the drug to help smokers quit.
An outside advisory committee was to consider the drug Wednesday.
|